HOME >> BIOLOGY >> NEWS
Terra spacecraft and ER-2 aircraft begin study of Southern Africa's environment

Pietersburg, South Africa -- NASA's Terra spacecraft and ER-2 high-altitude aircraft made their first synchronized scientific observations over Southern Africa today as part of the six-week Southern African Regional Science Initiative (SAFARI 2000) to study the region's ecosystems, air quality and land use.

The target on this first "stacked" flight was the haze in the atmosphere, specifically the gas carbon monoxide, which is a major component of air pollution. During the current dry season in Southern African, thick haze is produced by the burning of vegetation and industrial pollution sources. This haze can last for weeks over the region.

"I am quite pleased with the first coordinated flight of the ER-2 and Terra today," said Michael D. King of NASA's Goddard Space Flight Center, and SAFARI 2000 mission scientist for the ER-2. "We concentrated on comparing measurements of carbon monoxide and methane by Terra's MOPITT (Measurements of Pollution in the Troposphere) instrument and the ER-2's MOPITT-A instrument."

In addition, air samples along the spacecraft's track were collected by the South African Weather Bureau Aerocommander 690A aircraft. The South African plane, one of two participating in SAFARI 2000, made intricate spiral descents through the atmosphere to sample the haze.

Terra flew over the Indian Ocean along the eastern coast of Southern Africa today at 10:22 a.m. local time. Instruments onboard the ER-2 made measurements of the atmosphere at 60,000 feet along the spacecraft's track within minutes of the overpass. The aircraft then returned inland to sample the hazy air over South Africa.

"We're excited about the opportunity to fly with NASA's ER-2 for the first time in this campaign," said Bob Swap of the University of Virginia, principal investigator of the South African plane that flew today. "We're hoping that the information gathered from this flight will be valuable for the global observations of the atmosphere that MOPI
'"/>

Contact: Allen Kenitzer
allen.kenitzer@gsfc.nasa.gov
301-286-2806
NASA/Goddard Space Flight Center
17-Aug-2000


Page: 1 2

Related biology news :

1. An alternative form of chemotherapy? A means for reusable spacecraft?
2. NCAR aircraft, ground instruments to track carbon dioxide uptake
3. Beetles could prove a hit with the aircraft industry
4. From the bone of a horse, a new idea for aircraft structures
5. New Zealand aircraft to fly mission to USA McMurdo Station
6. Scientists, ships, aircraft to profile Asian pollution and dust
7. New hydrothermal vents discovered as South Pacific Odyssey research begins
8. DCI donor services begins distribution of tissue implants
9. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. Researchers begin study to protect against anthrax

Post Your Comments:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: